MedPal raises £5M at a 40% premium just three months after its last placing
What's the deal? MedPal AI, a UK digital health and AI company listed on London's AIM market, has raised approximately £5m in a share placing arranged by OAK Securities as sole broker. The company issued 142,857,133 new shares at 3.5 pence each, a 12.5% discount to its July 2 closing price but a 40% premium to its April 2026 placing.
Why now? The raise comes just three months after MedPal took in £3m in April, a fast re-raise. The timing tracks two events: the UK launch of the oral GLP-1 weight-loss pill oral Wegovy® on July 6, and a planned acquisition.
What's the endgame? Up to £3m will go toward stock and patient acquisition for the oral Wegovy® launch, with each active private patient forecast to generate £2,400 in annual recurring revenue. About £0.5m will fund the acquisition of Solid State Technologies, a profitable electronic Medicines Administration Record (eMAR) software business, to complete what MedPal calls a "closed-loop" care-home medication platform spanning prescribing, dispensing, administration, and reconciliation.
By the numbers: Solid State Technologies posted annualised revenue of about £843,000 and annualised profit of about £307,000 in management accounts to May 31, 2026. It will be acquired for a maximum £0.5m. The remaining proceeds strengthen working capital to support record NHS dispensing volumes.
What could go wrong? Much of the raise is a bet on a single new product. Oral Wegovy® exceeded three million US prescriptions since its January 2026 launch, but UK uptake and MedPal's ability to capture patients remain unproven.
The signal: A £5m placing is modest against a UK market that saw startups raise $23.7bn in 2025 and $14.5bn in the first five months of 2026, led by rounds like Nscale's $2.0bn Series C. But the premium pricing and quick turnaround suggest investor confidence, and sub-£5m raises still matter — helped by a new UK rule from January 2026 that eases prospectus rules for public raises up to £5m.
Read more: investegate.co.uk
Image credit: Generated with Gemini
